MacroGenics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics, including DART molecules and antibody-drug conjugates. Current reports record financial and operating results, FDA-related updates for the LINNET study of lorigerlimab, and material agreements involving ZYNYZ royalty rights under the Incyte collaboration.
Proxy and governance filings cover board elections, executive compensation, director matters and officer transitions. The filing record also addresses capital resources, collaboration and license economics, clinical-development disclosures, product-candidate updates and stockholder voting matters.
The Frazier Life Sciences reporting group disclosed specific holdings in MacroGenics common stock. Frazier Life Sciences Public Fund, L.P. directly holds 1,549,193 shares representing 2.5% of the 63,090,323 shares outstanding used for the percentage calculation. Other reporting entities hold 925,809 shares (1.5%), 575,150 shares (0.9%) and 125,513 shares (0.2%).
The filing states that voting and dispositive power for these shares is shared rather than sole and corrects prior attributions by clarifying that members of certain investment committees are not attributed beneficial ownership of the securities held by the respective funds. The statement also notes the reporters do not admit broader beneficial ownership or group status beyond what is disclosed.
MacroGenics appointed Eric Risser as President, Chief Executive Officer and elected him as a Class I director with a term expiring at the 2026 annual meeting. Mr. Risser, previously the company’s Chief Operating Officer, became the company’s principal executive officer effective August 13, 2025.
The company agreed an amended employment arrangement providing a $625,000 annual base salary, eligibility for annual incentive pay up to 60% of base salary, and a stock option to purchase 550,000 shares at the closing price on the effective date. Termination protections include cash severance (typically 1.0x salary plus 1.0x target bonus prorated, increased to 1.5x for change-of-control scenarios), COBRA premium coverage up to 18 months, and acceleration of unvested equity upon certain change-of-control terminations.
On 07/07/2025, Bellevue Group AG and its wholly-owned subsidiary, Bellevue Asset Management AG, filed a Schedule 13G revealing a 9,929,963-share position in MacroGenics, Inc. (MGNX) as of 06/01/2025. The stake equals 15.7 % of the company’s outstanding common stock. Both entities are incorporated in Switzerland and report shared voting and dispositive power over the entire holding, with zero sole voting or dispositive authority. Bellevue is classified as a “HC, CO” (parent holding company/control person) and Bellevue Asset Management AG as “CO.”
The certification states that the shares were acquired and are held in the ordinary course of business and are not intended to influence control of MacroGenics. This filing increases transparency around MacroGenics’ ownership structure and highlights a sizeable passive investment from a regulated Swiss financial institution.